# OnCo record paper-heinemann-fire-3-cetuximab-vs-bevacizumab-lancet-oncol-2014 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-heinemann-fire-3-cetuximab-vs-bevacizumab-lancet-oncol-2014" ;
schema:name "FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3)"@en ;
schema:description "A head-to-head of the two antibodies. They tied on response and progression, but patients on the EGFR antibody lived 3.7 months longer, a result nobody had predicted from the primary endpoint."@en ;
schema:url ;
schema:dateModified "2026-09-24"^^xsd:date ;
schema:citation , ;
onco:tag "colorectal-evidence" ;
schema:sameAs ;
schema:datePublished "2014"^^xsd:gYear ;
schema:author "Heinemann V, von Weikersthal LF, Decker T, et al." ;
onco:related , ;
onco:cancers ;
onco:sections ;
onco:technologies , ;
onco:targets , , ;
onco:drugs , , , ;
onco:terms ;
onco:trials ;
onco:people ;
onco:journals .